Skip to main content

Left Ventricular Hypertrophy clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

    open to eligible people ages 18-65

    This is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat versus standard of care therapy (agalsidase alfa, agalsidase beta, or migalastat) to evaluate the effect of venglustat on left ventricular mass index (LVMI) in adult participants with Fabry disease and left ventricular hypertrophy. - Study visits will take place approximately every 3 to 6 months - Participants who complete the randomized period may continue to the long-term extension (LTE) to receive venglustat for up to additional 34 months with the total study duration up to 4.4 years maximum.

    at UCLA

Last updated: